Investigation of natural products from medicinal cannabis as SARS-CoV-2 infectivity inhibitors
Planta Medica · 01.03.2026 · 92 (03) · 399-400
DOI: 10.1055/s-0045-1815406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von R Bahij und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The Cannabis sativa plant has been utilized across various cultures for diverse applications, including as a source of food, fiber, and medicinal compounds. Historical records suggest that the cultivation of Cannabis for medicinal use can be traced to approximately 2700 years ago [ 1 ]. The plant’s therapeutic properties, including antiviral activity, have been increasingly recognized, with cannabinoids and terpenes commonly identified as the primary bioactive constituents responsible for these effects [ 2 ]. In the present study, three distinct chemovars of Cannabis sativa were analyzed. A total of fourteen cannabinoids and thirteen terpenoids were identified using high-performance liquid chromatography with diode-array detection (HPLC-DAD), gas chromatography with flame ionization detection (GC-FID), and gas chromatography-mass spectrometry (GC-MS). Crude extracts from one of the chemovars were subjected to flash liquid chromatography (flash-LC) to obtain fractions. These crude extracts, their corresponding fractions, and isolated standard compounds were subsequently evaluated for antiviral activity using a cytopathic effect (CPE)-based bioassay with SARS-CoV-2 as the viral agent. The antiviral assessment indicated a potential correlation between the concentration of cannabinoids and terpenes and the observed antiviral efficacy. Notably, the full-spectrum extracts exhibited a higher antiviral effect compared to the fractions, while the isolated cannabinoids demonstrated the lowest activity. Among the tested cannabinoids, Δ 9 -tetrahydrocannabinolic acid (Δ 8 -THCA) showed higher antiviral potency than cannabidiol (CBD), with Δ 9 -tetrahydrocannabinol (Δ 8 -THC) exhibiting the lowest activity. These findings suggest that the antiviral properties of Cannabis sativa may be attributed to a synergistic interaction between multiple phytochemicals, rather than the effects of individual compounds alone. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Bahij, R., & Hansen, S. A. (2026). Investigation of natural products from medicinal cannabis as SARS-CoV-2 infectivity inhibitors. Planta Medica, 92(03), 399-400. https://doi.org/10.1055/s-0045-1815406
Vancouver
Bahij R, Hansen SA. Investigation of natural products from medicinal cannabis as SARS-CoV-2 infectivity inhibitors. Planta Medica. 2026;92(03):399-400. doi:10.1055/s-0045-1815406
BibTeX
@article{Bahij2026,
author = {Bahij, R and Hansen, S A},
title = {Investigation of natural products from medicinal cannabis as SARS-CoV-2 infectivity inhibitors},
journal = {Planta Medica},
year = {2026},
volume = {92},
number = {03},
pages = {399--400},
doi = {10.1055/s-0045-1815406}
}
EUVIMED